Brief: Exicure Presents Cavrotolimod (Ast-008) Clinical Data At AACR 2020 Virtual Meeting
22/06/2020 12:49
June 22 (Reuters) - Exicure Inc XCUR.O :
* EXICURE PRESENTS CAVROTOLIMOD (AST-008) CLINICAL DATA AT
AACR
2020 VIRTUAL MEETING
* EXICURE - CAVROTOLIMOD WAS WELL-TOLERATED
* EXICURE - NO CAVROTOLIMOD (AST-008)-RELATED SERIOUS
ADVERSE
EVENTS OR DOSE LIMITING TOXICITY HAVE BEEN REPORTED
Source text for Eikon: ID:nBw4Bk2zKa
Further company coverage: XCUR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Exicure
See all newsBrief: Exicure Announces 1-For-5 Reverse Stock Split
U.S. STOCKS ON THE MOVE-MercadoLibre, DoorDash, Coinbase
Brief: Exicure Inc Says Received Nasdaq Delinquency Notice On Late Filing Of Its Form 10-K
Brief: Exicure And Bluejay Therapeutics Enter Into A Patent License Agreement To Develop Cavrotolimod For The Treatment Of Hepatitis
Brief: Exicure Says Co Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq